Document Detail

Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions.
MedLine Citation:
PMID:  20955429     Owner:  NLM     Status:  MEDLINE    
Statins and antiplatelet agents are currently used as therapeutic agents for patients with acute myocardial infarction. Statins limit myocardial infarct size by activating phosphatidylinositol-3-kinase (PI3K), ecto-5'-nucleotidase, Akt/endothelial nitric oxide synthase (eNOS), and the downstream effectors inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Inhibition of PI3K, adenosine receptors, eNOS, iNOS, or COX-2 abrogates the protective effects of statins. At >5 mg/kg, aspirin attenuates the myocardial infarct-size-limiting effect of statins. In contrast, the combination of low-dose atoravastatin with either the phosphodiesterase-III inhibitor cilostazol or the adenosine reuptake inhibitor dipyridamole synergistically limits infarct size. Low-dose aspirin with dipyridamole started during ischemia augmented the infarct-size-limiting effects of simvastatin. In contrast, high-dose aspirin blocked the protective effect of simvastatin. The combination of dipyridamole with low-dose aspirin and simvastatin resulted in the smallest infarct size. According to the most current data available, we believe that antiplatelet regimens may require modification for patients who are receiving statins.
Yumei Ye; Jose R Perez-Polo; Yochai Birnbaum
Related Documents :
11286309 - The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial inf...
14965199 - Low-molecular weight heparins in percutaneous coronary interventions: current concepts,...
2109459 - Disseminated intravascular coagulation and myocardial infarction in a haemophilia b pat...
10639269 - The essence trial: efficacy and safety of subcutaneous enoxaparin in unstable angina an...
18657679 - Platelet inhibitor therapy: current perspectives and emerging novel agents: introduction.
17506599 - Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery dis...
21416259 - Heart failure pharmacogenetics: past, present, and future.
4012239 - Combined multiple-valve procedures. factors influencing the early and late results.
2373809 - Comparison of the natural history of new onset and exacerbated chronic ischemic heart d...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Annals of the New York Academy of Sciences     Volume:  1207     ISSN:  1749-6632     ISO Abbreviation:  Ann. N. Y. Acad. Sci.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-19     Completed Date:  2010-11-09     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  7506858     Medline TA:  Ann N Y Acad Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  76-82     Citation Subset:  IM    
Copyright Information:
© 2010 New York Academy of Sciences.
Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, Texas, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aspirin / administration & dosage
Dipyridamole / administration & dosage
Drug Interactions
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Models, Cardiovascular
Myocardial Infarction / drug therapy,  pathology,  physiopathology
Myocardial Reperfusion Injury / pathology,  physiopathology,  prevention & control*
Platelet Aggregation Inhibitors / administration & dosage*
Simvastatin / administration & dosage
Tetrazoles / administration & dosage
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Platelet Aggregation Inhibitors; 0/Tetrazoles; 50-78-2/Aspirin; 58-32-2/Dipyridamole; 79902-63-9/Simvastatin; N7Z035406B/cilostazol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of dipyridamole during acute stroke: exploring antithrombosis and neuroprotective benefits.
Next Document:  Reperfusion of chronic tissue ischemia: nitrite and dipyridamole regulation of innate immune respons...